Neuralink Receives FDA Approval for New ‘Blindsight’ Device to Restore Vision

Neuralink has achieved a significant milestone with its latest device, ‘Blindsight,’ which has received Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA). The company announced this on its official Twitter account, inviting people to join its patient registry or explore career opportunities on its website.

Elon Musk, CEO of Neuralink, added more details in a retweet, explaining that the Blindsight device aims to restore vision, even for individuals who have lost both eyes or their optic nerves. He mentioned that if the visual cortex remains functional, the device could even allow those who were blind from birth to see for the first time.

Musk noted that the initial vision might resemble low-resolution graphics, similar to old Atari games, but over time, the device could offer vision surpassing natural sight, with the possibility of seeing in infrared, ultraviolet, or even radar wavelengths. He expressed his gratitude to the FDA for their support.

Neuralink’s achievement marks a significant step forward in technology designed to improve the lives of those affected by vision loss.